贝伐单抗与重组人血管内皮抑素对人乳腺癌MCF-7细胞裸鼠移植瘤生长的影响

目的]探讨贝伐单抗、重组人血管内皮抑素对人乳腺癌MCF-7细胞裸鼠移植瘤生长的影响。方法]建立人乳腺癌裸鼠移植瘤模型，随机分为对照组、低剂量贝伐单抗组、高剂量贝伐单抗组、低剂量莺组人血管内皮抑素组、高剂量重组人血管内皮抑素组、低剂量联合组以及高剂量联合组，用药3周。检测裸鼠体重、移植瘤体积、移植瘤重量，计算抑瘤率。结果]与对照组相比，低剂量贝伐单抗组、高剂量贝伐单抗组、低剂量联合组、高剂量联合组裸鼠移植瘤生长曲线较平缓，移植瘤重量明显下降（P〈0．01），抑瘤率分别为67．69％、68．88％、78.32％和79．26％。低剂量联合组与低剂量贝伐单抗组移植瘤重量存在统计学差异（P〈0．05）。低剂量重组人血管内皮抑素组、高剂量重组人血管内皮抑素组移植瘤生长与对照组无统计学差异（P〉0．05）。结论]贝伐单抗能抑制人乳腺癌MCF-7细胞裸鼠移植瘤生长，低剂量贝伐单抗联合重组人血管内皮抑素能进一步提高抗肿瘤作用。

Effects of Bevacizumab and Recombinant Human Endostatin on Human Breast Cancer MCF-7 Xenografts in Nude Mice

Purpose] To investigate the effects of bevacizumab and recombinant human endostatin （rhES） on the tumor growth of human breast cancer MCF-7 xenografts in nude mice. Methods] Hu- man breast cancer xenografts were established from MCF-7 cells,and nude mice were randomly di- vided into control group,low-dose bevacizumab group,high-dose bevacizumab group,low-dose rhES group,high-dose rhES group,low-dose combination group and high-dose combination group. The body weight of nude mice,tumor volume and tumor weight were measured. The tumor inhibition rate was evaluated. Results ] Tumor weight was significantly decreased in low-dose bevacizumab group, high-dose bevacizumab group,low-dose combination group and high-dose combination group as com- pared with control （P〈0.01）. The tumor growth inhibition rates in low-dose bevacizumab group,high- dose bevacizumab group,low-dose combination group and high-dose combination group were 67.69%, 68.88% ,78.32% and 79.26% ,respectively. Significant difference in tumor weight between low-dose combination group and low-dose bevacizumab group was observed（P〈0.05）. There was no signifi- cant difference of tumor growth between rhES group and control group （P〉0.05）. Conclusion ] Beva- cizumab has an inhibitory effect on tumor growth of human breast cancer MCF-7 xenografts,and low- dose bevacizumab combined with rhES may enhance the antitumor activity.